This groundbreaking conference will seek answers to these questions:
> What progress is FDA making in implementing its Nanotechnology Task Force Report?
> What can FDA learn from EPA and other oversight agencies in NNI?
> Will the heavily Democratic Congress invest in and/or regulate more than under the Bush Administration?
> Are workers exposed to asbestos-like dangers from dealing with nano products?
> How does a responsible company devise a risk management plan for nanotech development -- one that takes into account OSHA and NIOSH policy?
> What is reasonable and required federal funding for U.S nanotechnology R&D, including monies for safety and social policy research?
> Are China and Japan ahead of the U.S. in nanotech development?
> For nanotech products and processes, should particle size make a regulatory difference?
Other featured speakers and moderators include:
Scott Livingston, Capital Management/The Livingston Group
Andrew Maynard, Woodrow Wilson International Center for Scholars
George Burdock, Burdock Group
Tie Lan, NanoCor Inc.
Robert J. Nicolosi,
Matthew Jaffe, Crowell & Moring, LLP
Les Makepeace, Colorado Nanotechnology Alliance
Sean Murdock, NanoBusiness Alliance
Jay Ansell, Personal Care Products Council
James Chen, Crowell & Moring, LLP
John Howard, Public Health Law Program, Center
|SOURCE Food and Drug Law Institute|
Copyright©2009 PR Newswire.
All rights reserved